Performance of mixed effects models for partially clustered trials

Performance of mixed effects models for partially clustered trials

<p dir="ltr">Poster presentation for the International Society of Clinical Biostatistics conference Milan, Italy, August 2023</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Kylie Lange (4204294) (author)
مؤلفون آخرون:	Thomas R. Sullivan (8967980) (author), Jessica Kasza (17312128) (author), Lisa Yelland (4203580) (author)
منشور في:	2025
الموضوعات:	Biostatistics clinical trials simulation clustering
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Protocol for the Delphi study on checklist for the reporting of sample size in trial grant application and protocols for adaptive design
حسب: Qiang Zhang (11637799)
منشور في: (2025)

Supplementary Figure S1 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Supplementary Figure S2 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Supplementary Figure S3 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Supplementary Figure S4 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Supplementary Figure S5 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Supplementary Figure S6 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Supplementary Figure S7 from Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
حسب: Kai Chen (21631060)
منشور في: (2025)

Assessing allocation bias in stratified clinical trials with multi-component endpoints evaluated using the stratified Wei-Lachin test
حسب: Stefanie Schoenen (22579433)
منشور في: (2025)

Figure 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
حسب: Walter M. Gregory (14932587)
منشور في: (2025)

Figure 2 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
حسب: Walter M. Gregory (14932587)
منشور في: (2025)

Figure 3 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
حسب: Walter M. Gregory (14932587)
منشور في: (2025)

Figure 4 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
حسب: Walter M. Gregory (14932587)
منشور في: (2025)

Figure 5 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
حسب: Walter M. Gregory (14932587)
منشور في: (2025)

Figure 6 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
حسب: Walter M. Gregory (14932587)
منشور في: (2025)

Guidelines for benchmarking and outlier detection in clinical quality registries - simulation and model build code
حسب: Jessy Hansen (17185192)
منشور في: (2025)

Ethics in Clinical Research, E-Module Versus Traditional Online Lecture, a Randomized Study
حسب: Lynette M. Smith (10180637)
منشور في: (2025)

Building a Data Strategy: Key Steps for Aligning Your Research Methodology with Your Research Goal
حسب: Felix Emeka Anyiam (18307579)
منشور في: (2025)

Outlier detection in clinical registries - simulation study data and Stata code
حسب: Jessy Hansen (17185192)
منشور في: (2024)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
حسب: Alessio Cortellini (11023993)
منشور في: (2025)

Accuracy of site benchmarking in clinical quality registries of varying size - simulation study data and Stata code
حسب: Jessy Hansen (17185192)
منشور في: (2025)

Simulation code for evaluating randomization procedures in group sequential designs
حسب: Daniel Bodden (21000344)
منشور في: (2025)

Parameter estimates of mixed generalized Gaussian distribution for modelling the increments of electroencephalogram data
حسب: Zoe Salinger (19090613)
منشور في: (2024)

Figure S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Figure S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Table S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Table S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
حسب: Gulam A. Manji (9379203)
منشور في: (2024)

Supplemental Figure S1 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
حسب: Rosalie Griffin (14855470)
منشور في: (2025)

Supplemental Figure S2 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
حسب: Rosalie Griffin (14855470)
منشور في: (2025)

Supplemental Figure S3 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
حسب: Rosalie Griffin (14855470)
منشور في: (2025)

Supplemental Figure S4 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
حسب: Rosalie Griffin (14855470)
منشور في: (2025)

Supplemental Figure S5 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
حسب: Rosalie Griffin (14855470)
منشور في: (2025)

Supplemental Figure S6 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
حسب: Rosalie Griffin (14855470)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ad94as37b80p0o0prp45rctkmr